In the News

March 19, 2010, AOL DailyFinance: "Inside Wall Street: Resverlogix Is a Baby Biotech That Could Grow Up Fast", by Gene Marcial. Link:  http://www.dailyfinance.com/story/investing/inside-wall-street-resverlogix-is-a-baby-biotech-that-could-gro/19405436/

March 11, 2010, BusinessWeek article: "The Quest to Boost Good Cholesterol", by Ellen Gibson. Link: http://www.businessweek.com/magazine/content/10_12/b4171070637300.htm?campaign_id=rss_topStories

March 5, 2010, Bloomberg BusinessWeek article: "Pfizer Cholesterol Flops Cleared Path for Resverlogix", by Ellen Gibson. Link: http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aDaRLM2Pu8YA

 

 

About Resverlogix Corp

We are a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas™ program is our primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer’s disease and other vascular disorders. Our secondary focus is TGF-beta Shield™, a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX).

Our Product Development

NexVas™ Plaque Regression (NexVas PR) is a technology platform for the development of drugs that increase ApoA-I to reduce the risk of cardiovascular diseases. Our lead drug RVX-208 is currently in two Phase 2 Clinical Trials "ASSERT" and "ASSURE 1" with the Cleveland Clinic.

NexVas™ Vascular Inflammation (NexVas VI) is a preclinical technology for the development of drugs that target molecular markers of inflammation.

NexVas™ Alzheimer's Disease (NexVas AD) is a technology in Phase 1 for the development of drugs that enhance ApoA-I for stabilization and regression of Beta Amyloid Plaque.   

ReVas™ is a discovery stage technology for the development of therapeutics to be used with medical devices for the treatment of cardiovascular diseases. ReVas is partnered with Medtronic Inc. 

 

Email Print SmallMediumLargeChoose Font Size
What's New
June 22, 2010
Download PDFRVX 2nd Financing Closes
June 22, 2010
Download PDFRVX Presents Data at EAS
NEXVAS™ Animation
View NexVas™ Animation
Annual Report 2009
View 2009 Annual Report